

Stabilitätspakt für Südosteuropa Gefördert durch Deutschland Stability Pact for South Eastern Europe ISponsored by Germany



## POSSIBILITIES FOR FORMULATION OF TRASTUZUMAB - RADIOIMMUNOGONJUGATES

## <u>Marija Sterjova<sup>1</sup>, Predrag Dzodic<sup>2</sup>, Paulina Apostolova<sup>1</sup>, Emilija Janevik<sup>1</sup></u>

<sup>1</sup>University Goce Delcev, Faculty of Medical Sciences, Stip, Republic of Macedonia <sup>2</sup>University in Nis, Medical Faculty, str. "Zoran Dindic" No. 81, 18000 Nis, Serbia

## Discussion:



Conjugation of BFC for HER2-targeting trastuzumab, and labeling with Ga-68.

In vitro characterization and in vivo biodistribution of <sup>68</sup>Galabeled conjugates.

## Conclusion:

The simplicity and efficiency of labelling with <sup>68</sup>Ga tracer will greatly increase <sup>68</sup>Ga PET access to hospitals, expanding the use of the <sup>68</sup>Ga generator.

In the same time give opportunity to work on the same or similar kit formulation using with Lu-177 for therapy.



Fig. 4 Ga-68 Generator